Patients file lawsuits against Novo Nordisk and Eli Lilly over vision loss linked to GLP-1 drugs
Solo los hechos

Patients file lawsuits against Novo Nordisk and Eli Lilly over vision loss linked to GLP-1 drugs

Resumen

Several individuals have sued Novo Nordisk and Eli Lilly, alleging that their GLP-1 weight-loss medications caused sudden vision loss, while experts note that scientific evidence on the link remains inconclusive.

Patients have filed lawsuits against Novo Nordisk, maker of Wegovy and Ozempic, and Eli Lilly, maker of Zepbound, claiming the drugs triggered a rare eye condition that caused sudden vision loss. The plaintiffs were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), a disorder that can lead to permanent visual impairment.

Research published abroad suggests GLP-1 medications may increase the risk of NAION, prompting some countries to require warning labels. In the United States, the Food and Drug Administration has not mandated such warnings, though it is reviewing the potential association. Experts note that NAION lacks a specific diagnostic code, complicating efforts to track cases, and that many GLP-1 users have other risk factors such as diabetes, cardiovascular disease, hypertension, or sleep apnea.

The lawsuits allege that the companies did not adequately inform patients about the possible eye-related side effect, while the manufacturers and some medical professionals contend that the scientific data linking the drugs to NAION is mixed.

Sigue leyendo, gratis

Crea una cuenta gratis para seguir las noticias. No se requiere tarjeta.